Localised dMMR Colon Cancer research hub

Neoadjuvant Immunotherapy and Organ-sparing Treatment in Patients with Stage I-III dMMR Colon Cancer: A National, Multicentre, Personalised, Phase II Study (RESET C2)

RESET C2 is a study looking at a new way to treat early colon cancer that has a specific genetic marker (dMMR). It uses an immunotherapy drug (Keytruda) before surgery, aiming to shrink the cancer so surgery might not be needed, or to make it less extensive.